Select Page

Flamicort 4mg tablets

Dexa Medica

Product packaging may vary from one country to another.

Ingredients in every tablet

Triamcinolone 4 mg

Each package contains

5 strips of 10 tablets

Other details

Dosage form:Tablet; plain
Flavour None

W.H.O. classification

ATC Level 1 H - Systemic hormonal preparations; excluding sex hormones and insulins
ATC Level 2 H02 - Corticosteroids for Systemic Use
ATC Level 3 H02A - Corticosteroids for Systemic Use; Plain

Warnings

Pregnancy

CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.

Lactation

CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia

Dosage information

18 YEARS OLD AND ABOVE
Initial dose: 4-48 mg per day, depending on the specific disease entity being treated.
The initial dosage should be maintained or adjusted until a satisfactory response is noted.

0 TO 18 YEARS OLD
The dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient rather than by strict adherence to the ratio indicated by age or body weight. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.

TRANSFER PATIENTS FROM OTHER CORTICOSTEROIDS
Substitute triamcinolone 4 mg initially in place of each cortisone 25 mg, hydrocortisone 20 mg, prednisone 5 mg, prednisolone 5 mg, methylprednisolone 4 mg, dexamethasone 0.75 mg, betamethasone 0.6 mg, paramethasone 2 mg. Thereafter, dosage should be adjusted according to individual response.

Indication

Treatment for the following conditions:

Endocrine disorders
Primary or secondary adrenocortical insufficiency (hydrocortisones or cortisones are the drugs of choice although synthetic analogs may be used in conjunction with mineralocorticoids where applicable, mineralocorticoid supplementation is of particular importance when treating this condition in infants); congenital adrenal hyperplasia; nonsuppurative thyroiditis; and hypercalcemia associated with cancer.

Rheumatic disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in psoriatic arthritis; rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis, post-traumatic osteoarthritis; synovitis of osteoarthritis; and epicondylitis.

Collagen diseases
For use during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus and acute rheumatic carditis.

Dermatologic diseases
Pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, mycosis fungoides and severe psoriasis.

Allergic states
For the control of seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, angioedema and urticaria when they are severe or incapacitating and intractable to adequate trials of conventional treatment.

Ophthalmic diseases
Severe, acute and chronic allergic and inflammatory processes involving the eye and its associated anatomic parts e.g., allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, anterior segment inflammation, diffuse posterior uveitis and choroiditis, optic neuritis and sympathetic ophthalmia.

Respiratory diseases
Symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when concurrently accompanied by appropriate antituberculous chemotherapy, pulmonary emphysema where bronchospasm or bronchial edema plays a significant role and diffuse interstitial pulmonary fibrosis (Hamman-Rich syndrome).

Hematologic disorders
Idiopathic and secondary thrombocytopenia in Adults, acquired (auto-immune) hemolytic anemia, erythroblastopenia (RBC anemia) and congenital (erythroid) hypoplastic anemia.

Neoplastic diseases
For palliative management of leukemias and lymphomas in Adults and acute leukemia in childhood.

Edematous states
To induce diuresis or remission of proteinuria in the nephrotic syndrome (non-uremic, the idiopathic type or that which is due to lupus erythematosus) and, in conjunction with diuretic agents, to induce diuresis in refractory congestive heart failure and in cirrhosis of the liver with refractory ascites.

Gastrointestinal diseases
To tide the patient over a critical period of the disease in ulcerative colitis, regional enteritis and intractable sprue.

Miscellaneous
Dental postoperative inflammatory reactions and tuberculous meningitis with subarachnoid block or impending block when concurrently accompanied by appropriate antituberculous chemotherapy.